Inflammation (Ulcerative Colitis)
Ogeda has identified and patentent compounds, including ESN282, against free fatty acid receptor 2 (FFAR2/GPR43) for the potential treatment of inflammatory diseases such as ulcerative colitis. Ogeda entered a collaboration with Merck Sharp and Dohme under which it was awarded up-front and initial milestone payments along with ongoing research funding to support the program. Ogeda has now regained all rights to ESN282.
Ogeda’s drug discovery activities are focused on G-Protein Coupled Receptor (GPCRs) targets where there is significant market opportunity and where we have identified clear, competitive advantages in drug discovery and development.
Ogeda believes in investigating new target ideas, and has attained leadership in novel approaches relevant to the treatment of endocrine, CNS and/or inflammatory disorders. Ogeda aims to rapidly validate its drug development candidates through either internal investment to clinical proof-of-concept or external investment in case of corporate partnering.
Ogeda’s research is covered by more than 80 pending and granted patents in around nine families covering various aspects of discovery, generation, optimization, manufacturing, administration and clinical use of its small molecule drug candidates.